在患有喘和慢性阻塞性肺病的患者中,对各种生物药物的反应
Marek Lommatzsch1, Sebastian Niels Mohme1, Paul Stoll1
1Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.
Respiration; international review of thoracic diseases
|November 20, 2023
概括
生物药物在治疗慢性阻塞性肺病 (COPD) 和喘患者中表现出有效性,改善了恶化,控制喘和肺功能. 本研究提出了这个复杂的患者群体的定义.
科学领域:
- 肺部病理学 肺部病理学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 同时存在的慢性阻塞性肺病 (COPD) 和喘带来了诊断和治疗方面的挑战.
- 关于生物疗法在患有重叠COPD和喘特征的患者中有效性的数据有限.
- 目前的临床实践中对这一患者群体缺乏准确的定义.
研究的目的:
- 评估COPD和喘患者生物治疗的有效性.
- 提出一种实际的定义,用于识别患有慢性肺炎和喘同时存在的患者.
主要方法:
- 通过吸烟史,螺旋计 (FEV1/FVC,FEV1),DLCO和症状来定义COPD.
- 根据2型生物标志物 (乙氨基,FeNO),临床特征和葡萄糖皮质激素反应来定义喘.
- 分析了20名患有这两种疾病的患者的数据,这些患者在治疗复发性恶化时使用生物药物.
主要成果:
- 生物治疗 (中位数为12个月) 显著减少了恶化,改善了喘控制和增强了肺功能.
- 治疗前的中位数包括40个包装年,42%预测FEV1,45%预测DLCO,475个乙素/μL和48个ppbFeNO.
- 观察到的改善在减轻恶化方面最为突出.
结论:
- 已批准用于治疗严重喘的生物药物在患有并发性慢性肺炎和喘的患者中有效.
- 这项研究表明,在常规临床环境中,这个患者群体的定义很容易适用.
更多相关视频
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
22.5K
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
7.7K
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
452
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
452
01:26COPD: Management Using Bronchodilators and Corticosteroids
214
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
214
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
272
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
272
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
307
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
307
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
276
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
276
01:19Antiasthma Drugs: Leukotriene Modifiers
321
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
321